All In Biotech

Drug Trial Radar · NCT04622319

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,600

Planned (sponsor's estimate)

Start

Dec 4, 2020

Primary completion

Jul 2, 2025

Study completion Jun 20, 2028

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca; NSABP Foundation Inc; GBG Forschungs GmbH; Spanish Breast Cancer Research Group
First posted
Nov 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

Conditions

  • HER2-Positive Primary Breast Cancer
  • Residual Invasive Breast Cancer

Interventions

  • DS-8201aDrug

    Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle

  • T-DM1Drug

    Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) TreatmentTime frame: Randomization to date of invasive local, axillary or distant recurrence, invasive contralateral breast cancer or death from any cause (whichever occurs first), up to approximately 57 months postdose

Locations

482 sites in 31 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope & Innovation

    Anaheim, California

  • Kaiser Permanente

    Anaheim, California

  • Kaiser Permanente

    Baldwin Park, California

  • Kaiser Permanente

    Bellflower, California

  • Kaiser Permanente

    Fontana, California

  • Orange Coast Blood and Cancer Care

    Fountain Valley, California

  • Kaiser Permanente

    Harbor City, California

  • Kaiser Permanente

    Irvine, California

  • Long Beach Memorial TCI

    Long Beach, California

  • Kaiser Permanente

    Los Angeles, California

  • Kaiser Permanente

    Ontario, California

  • Kaiser Permanente

    Panorama City, California

  • Kaiser Permanente

    Riverside, California

  • Kaiser Permanente

    San Diego, California

  • Kaiser Permanente

    San Marcos, California

  • Kaiser Permanente

    West Los Angeles, California

  • Kaiser Permanente

    Woodland Hills, California

  • SCRI FCS North- Altamonte

    Altamonte Springs, Florida

  • SCRI FCS South- Bonita

    Bonita Springs, Florida

  • SCRI FCS North- Brandon Cancer Center

    Brandon, Florida

  • SCRI FCS South- North Fort Myers

    Cape Coral, Florida

  • SCRI FCS North- Mease/Clearwater

    Clearwater, Florida

  • SCRI FCS South

    Fort Myers, Florida

  • SCRI FCS South- Colonial

    Fort Myers, Florida

  • SCRI FCS South- Gladiolus

    Fort Myers, Florida

  • SCRI FCS North- Gainesville Cancer Center

    Gainesville, Florida

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida

  • SCRI FCS North- Villages East

    Lady Lake, Florida

  • SCRI FCS South- Lakewood Ranch

    Lakewood Rch, Florida

  • SCRI FCS North- Largo/Highland

    Largo, Florida

  • SCRI FCS North- Lecanto

    Lecanto, Florida

  • SCRI FCS South- Naples West

    Naples, Florida

  • SCRI FCS South- Naples/Goodlette

    Naples, Florida

  • SCRI FCS North- New Port Richey

    New Port Richey, Florida

  • SCRI FCS North- Ocala

    Ocala, Florida

  • Orlando Health

    Ocoee, Florida

  • SCRI FCS North- Orange City

    Orange City, Florida

  • Orlando Health

    Orlando, Florida

  • SCRI FCS North- Orlando Downtown

    Orlando, Florida

  • SCRI FCS South- Port Charlotte

    Port Charlotte, Florida

Showing 40 of 482 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.